- Investing Ideas
- /
- Swedish Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Swedish Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
5
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
5 companies
BioGaia
Market Cap: SEK 9.6b
A healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand.
BIOG B
SEK 94.45
7D
-1.0%
1Y
-25.7%
Vitrolife
Market Cap: SEK 18.3b
Provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas.
VITR
SEK 135.50
7D
-4.0%
1Y
-38.4%
Bonesupport Holding
Market Cap: SEK 20.5b
An orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally.
BONEX
SEK 310.80
7D
-3.9%
1Y
10.8%
Genovis AB (publ.)
Market Cap: SEK 1.7b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 26.25
7D
-1.5%
1Y
-13.2%
AddLife
Market Cap: SEK 20.0b
Provides equipment, consumables, and reagents primarily to healthcare sector, research, colleges, and universities, as well as the food and pharmaceutical industries.
ALIF B
SEK 164.40
7D
-3.1%
1Y
6.8%